Clinical Trials Logo

JMML clinical trials

View clinical trials related to JMML.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05849662 Not yet recruiting - Neurofibromatosis 1 Clinical Trials

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Start date: November 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.